Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: atorvastatin calcium

« Back to Dashboard
Atorvastatin calcium is the generic ingredient in three branded drugs marketed by Apotex Inc, Dr Reddys Labs Ltd, Kudco Ireland, Mylan Pharms Inc, Ranbaxy Labs Ltd, Sandoz Inc, Teva Pharms, Pfizer, and Merck Sharp Dohme, and is included in ten NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are fifty-seven drug master file entries for atorvastatin calcium. Seventeen suppliers are listed for this compound.

Summary for Generic Name: atorvastatin calcium

Tradenames:3
Patents:3
Applicants:9
NDAs:10
Drug Master File Entries: see list57
Suppliers: see list17
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: atorvastatin calcium

Clinical Trials for: atorvastatin calcium

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers
Status: Completed Condition: Healthy

Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy
Status: Withdrawn Condition: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL078773-003May 29, 2012DISCNNo<disabled><disabled>
Teva Pharms
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL078773-002May 29, 2012DISCNNo<disabled><disabled>
Merck Sharp Dohme
LIPTRUZET
atorvastatin calcium; ezetimibe
TABLET;ORAL200153-001May 3, 2013RXNoRE42461*PED<disabled><disabled>
Merck Sharp Dohme
LIPTRUZET
atorvastatin calcium; ezetimibe
TABLET;ORAL200153-002May 3, 2013RXNo<disabled><disabled>
Merck Sharp Dohme
LIPTRUZET
atorvastatin calcium; ezetimibe
TABLET;ORAL200153-004May 3, 2013RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc